Trials / Approved For Marketing
Approved For MarketingNCT06003881
Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy
An Open-Label, Expanded Access Program of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- —
Summary
The program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy (PLE). CD55-deficient PLE/CHAPLE disease is a rare inherited disease of the immune system. This can be a life-threatening condition that is usually found when patients are children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pozelimab | Subcutaneous (SC) administration |
Timeline
- First posted
- 2023-08-22
- Last updated
- 2025-11-10
Source: ClinicalTrials.gov record NCT06003881. Inclusion in this directory is not an endorsement.